Tirzepatide SDS: What the Safety Data Sheet Actually Tells You

The common misconception: thinking the SDS is what patients need to read

Most people who land on a tirzepatide SDS search have the right instinct (they want to understand how safe this medicine is) but they have arrived at the wrong document. A Safety Data Sheet is produced under occupational health and chemical-handling regulations. It covers things like what to do if the bulk substance is spilled in a manufacturing environment, what personal protective equipment laboratory staff should wear, and how the compound behaves at industrial concentrations. None of that is relevant to someone injecting a tiny therapeutic dose from a pre-filled KwikPen at home.

The confusion is understandable. SDS is a familiar acronym from science classrooms and workplace safety training, so it seems like a logical term to search when you want "the official safety information". But for any licensed medicine, the documents that actually answer patient questions are the SmPC (written for prescribers and pharmacists) and the Patient Information Leaflet (written for patients). Both are freely accessible on the Electronic Medicines Compendium and are approved by the MHRA before the medicine is sold in the UK.

The tirzepatide overview on our site covers the clinical picture in plain language if you want a readable starting point before going into the full SmPC.

What the SmPC and Patient Information Leaflet actually contain

If you want tirzepatide's real safety profile, the SmPC is the authoritative source. It lists contraindications, conditions that rule out use entirely, such as a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. It details precautions, including the need to discuss any history of pancreatitis with your prescriber before starting. And it documents the side-effect profile in clinical-grade detail.

The side effects most commonly reported in trials are gastrointestinal: nausea, loose stools, constipation, indigestion and reflux tend to appear most in the first few weeks, particularly after starting or after a dose increase, then settle for most people as the body adjusts. In January 2026 the MHRA issued a specific Drug Safety Update highlighting acute pancreatitis as a known but infrequent risk with GLP-1 medicines as a class, severe stomach pain that spreads to the back, with or without vomiting, should prompt urgent medical attention. You can read that update and report any suspected side effects through the MHRA Yellow Card scheme.

Tirzepatide carries Black Triangle (▼) status in the UK, which simply means that, as a relatively new medicine, the MHRA is collecting enhanced safety data. It does not mean the medicine is considered especially dangerous; it means regulators want a richer post-market evidence base, which is sensible for a medicine prescribed at scale.

The NHS medicines page for tirzepatide provides a reliable plain-English summary of both common and serious side effects worth bookmarking alongside the SmPC.

Tirzepatide's licensed use and who it is for

Tirzepatide, sold under the brand name Mounjaro by Eli Lilly, works as a dual GIP and GLP-1 receptor agonist. It is the only medicine of this class licensed for weight management in the UK. By activating both receptor pathways, it reduces appetite, slows gastric emptying and influences blood-sugar regulation, a mechanism distinct from semaglutide, which acts on GLP-1 alone. You can read a detailed comparison on the Mounjaro versus tirzepatide page.

In the UK it is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, raised cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. It is not licensed for use in people under 18, and it is not recommended during pregnancy, breastfeeding or when actively trying to conceive.

Treatment starts at 2.5 mg (a dose whose purpose is to let your body adjust, not to produce the therapeutic effect) and is titrated by a prescriber, typically in four-week steps, up through 5, 7.5, 10, 12.5 and 15 mg. Deciding where to stop, or whether to continue, is a clinical judgement. Information about the 10 mg stage of treatment gives a sense of what the middle doses involve.

For context on private treatment costs, the Mounjaro pricing page sets out what you can expect from the UK private market honestly, without obscuring what different providers include in their headline figures.

Getting accurate information about tirzepatide before you start

There is a real gap between what an SDS tells you and what a patient considering tirzepatide actually needs to know. The SDS exists for a controlled industrial environment; the SmPC and Patient Information Leaflet exist for clinical use. A prescriber exists for the questions neither document answers neatly, which, frankly, is most of the questions people actually have.

A question our prescribers hear most weeks is some version of "I've read a lot online, but I don't know which bits apply to me." That is the right problem to bring to a clinical consultation, not to a safety data sheet. The weight loss treatment overview explains how a clinical route works in practice, including what happens if tirzepatide turns out not to be appropriate. Our clinical team handles each consultation personally, a named prescriber reads your answers the same day, not software. If you have specific concerns about your medical history and whether tirzepatide is suitable for you, that conversation belongs with a prescriber, and our pages covering tirzepatide l and the tirzepatide 30 dose can help you understand the range of options before you start that conversation. When you're ready, you can check your eligibility through a free consultation.